EGFR and non-small cell lung carcinoma: However, in retrospectively assessed cohorts of patients with advanced EGFRM+ NSCLC, the occurrence of PIK3CA co-mutations at baseline, despite being a negative prognostic factor, did not necessarily interfere with the effect of EGFR-TKI monotherapy in terms of RR, PFS, and duration of response [51,52,53,174].